Phase 3 · NCT06662383
TRIUMPH-5
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity
Registry record
Trial details
- Trial
- TRIUMPH-5
- ClinicalTrials.gov ID
- NCT06662383
- Indication
- Obesity
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 800
- Status
- Active, not recruiting
- Interventions
- Drug: Retatrutide; Drug: Tirzepatide
- Comparator
- Not reported
- Eligible ages
- 18 Years – No maximum
- Locations
- 65 sites · Argentina, Germany, Poland, Puerto Rico, United States
- Study start
- 1 Nov 2024
- Primary completion
- 1 Nov 2026
- Study completion
- 1 Dec 2026
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 20 Jul 2026
Endpoints
Primary
Percent Change from Baseline in Body Weight
Secondary
Change from Baseline in Body Mass Index (BMI); Change from Baseline in Waist Circumference; Percent Change from Baseline in Total Cholesterol; Percent Change from Baseline in Triglycerides; Change from Baseline in Systolic Blood Pressure (SBP); Change from Baseline in Diastolic Blood Pressure (DBP); Change from Baseline in Hemoglobin A1c (HbA1c); Percent Change from Baseline in Fasting Insulin; Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)
Registry monitoring
Latest Trial Changes
| Field | Change | Detected | Source |
|---|---|---|---|
| Recruitment status | Recruiting→Active, not recruiting | 4 Sept 2026 | ClinicalTrials.gov |
| Enrolment | 760→800 | 4 Sept 2026 | ClinicalTrials.gov |
| Primary completion date | 2027-12-31→2026-11-01 | 4 Sept 2026 | ClinicalTrials.gov |
| Study completion date | Data pending→2026-12-01 | 4 Sept 2026 | ClinicalTrials.gov |
| Primary endpoints | Data pending→Percent Change from Baseline in Body Weight | 4 Sept 2026 | ClinicalTrials.gov |